0000899243-20-003484.txt : 20200206 0000899243-20-003484.hdr.sgml : 20200206 20200206161957 ACCESSION NUMBER: 0000899243-20-003484 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200204 FILED AS OF DATE: 20200206 DATE AS OF CHANGE: 20200206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MUEHL DANIEL W CENTRAL INDEX KEY: 0001283569 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 20582938 MAIL ADDRESS: STREET 1: 5 BILLERICA PARK STREET 2: 101 BILLERICA AVE CITY: NORTH BILLERCA STATE: MA ZIP: 01862 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-04 0 0001466301 Clovis Oncology, Inc. CLVS 0001283569 MUEHL DANIEL W C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2020-02-04 4 M 0 10226 A 20160 D Common Stock 2020-02-04 4 S 0 5043 8.41 D 15117 D Common Stock 2020-02-04 4 M 0 12271 A 27388 D Common Stock 2020-02-04 4 S 0 5429 8.41 D 21959 D Restricted Stock Units 2020-02-04 4 M 0 22497 0.00 D Common Stock 22497 67485 D Each Restricted Stock Unit represents the right to receive one share of Common Stock. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. On February 1, 2019, the reporting person was granted 89,982 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Executive Vice President and Chief Financial Officer /s/ Daniel W. Muehl 2020-02-06